BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32372453)

  • 1. Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan.
    Onuki M; Matsumoto K; Iwata T; Yamamoto K; Aoki Y; Maenohara S; Tsuda N; Kamiura S; Takehara K; Horie K; Tasaka N; Yahata H; Takei Y; Aoki Y; Kato H; Motohara T; Nakamura K; Ishikawa M; Kato T; Yoshida H; Matsumura N; Nakai H; Shigeta S; Takahashi F; Noda K; Yaegashi N; Yoshikawa H
    Cancer Sci; 2020 Jul; 111(7):2546-2557. PubMed ID: 32372453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer.
    Onuki M; Matsumoto K; Satoh T; Oki A; Okada S; Minaguchi T; Ochi H; Nakao S; Someya K; Yamada N; Hamada H; Yoshikawa H
    Cancer Sci; 2009 Jul; 100(7):1312-6. PubMed ID: 19432906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
    Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
    J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
    Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
    Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.
    Bukowski A; Hoyo C; Hudgens MG; Brewster WR; Valea F; Bentley RC; Vidal AC; Maguire RL; Schmitt JW; Murphy SK; North KE; Smith JS
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1564-1571. PubMed ID: 35654413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of human papilloma virus genotype prevalence in invasive cervical carcinomas and precancerous lesions in the Yangtze River Delta area, China.
    Wang H; Cheng X; Ye J; Xu X; Hong Y; Sui L; You Z; Xie X
    BMC Cancer; 2018 Apr; 18(1):487. PubMed ID: 29703167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.
    Clarke MA; Gradissimo A; Schiffman M; Lam J; Sollecito CC; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Castle PE; Wentzensen N; Burk RD
    Clin Cancer Res; 2018 May; 24(9):2194-2202. PubMed ID: 29420222
    [No Abstract]   [Full Text] [Related]  

  • 10. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
    Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
    Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention.
    Dovey de la Cour C; Guleria S; Nygård M; Trygvadóttir L; Sigurdsson K; Liaw KL; Hortlund M; Lagheden C; Hansen BT; Munk C; Dillner J; Kjaer SK
    Cancer Med; 2019 Feb; 8(2):839-849. PubMed ID: 30632704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.
    Joura EA; Ault KA; Bosch FX; Brown D; Cuzick J; Ferris D; Garland SM; Giuliano AR; Hernandez-Avila M; Huh W; Iversen OE; Kjaer SK; Luna J; Miller D; Monsonego J; Munoz N; Myers E; Paavonen J; Pitisuttithum P; Steben M; Wheeler CM; Perez G; Saah A; Luxembourg A; Sings HL; Velicer C
    Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):1997-2008. PubMed ID: 25274978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
    Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
    J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of high-risk human papillomavirus and cervical lesion risk factors: A population-based study in Zhejiang, China 2010-2019.
    Lu W; Chen T; Yao Y; Chen P
    J Med Virol; 2021 Aug; 93(8):5118-5125. PubMed ID: 33913528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
    McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
    Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
    J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia.
    Quek SC; Lim BK; Domingo E; Soon R; Park JS; Vu TN; Tay EH; Le QT; Kim YT; Vu BQ; Cao NT; Limson G; Pham VT; Molijn A; Ramakrishnan G; Chen J
    Int J Gynecol Cancer; 2013 Jan; 23(1):148-56. PubMed ID: 23221730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis.
    Palmer M; Katanoda K; Saito E; Acuti Martellucci C; Tanaka S; Ikeda S; Sakamoto H; Machelek D; Ml Brotherton J; Hocking JS
    Vaccine; 2022 Sep; 40(41):5971-5996. PubMed ID: 36085257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
    Onuki M; Yamamoto K; Yahata H; Kanao H; Yokota H; Kato H; Shimamoto K; Takehara K; Kamiura S; Tsuda N; Takei Y; Shigeta S; Matsumura N; Yoshida H; Motohara T; Watari H; Nakamura K; Ueda A; Tasaka N; Ishikawa M; Hirashima Y; Kudaka W; Taguchi A; Iwata T; Takahashi F; Kukimoto I; Yoshikawa H; Yaegashi N; Matsumoto K;
    Cancer Sci; 2022 Apr; 113(4):1428-1434. PubMed ID: 35043515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.